Be Wary Of Winning Health Technology Group (SZSE:300253) And Its Returns On Capital
Be Wary Of Winning Health Technology Group (SZSE:300253) And Its Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. In light of that, when we looked at Winning Health Technology Group (SZSE:300253) and its ROCE trend, we weren't exactly thrilled.
如果你在尋找下一款多功能裝袋機時不確定從哪裏開始,那麼你應該留意一些關鍵趨勢。理想情況下,企業將表現出兩種趨勢;首先是增長 返回 論資本使用率(ROCE),其次是增加 金額 所用資本的比例。這向我們表明,它是一臺複合機器,能夠持續將其收益再投資到業務中併產生更高的回報。有鑑於此,當我們研究Winning Health Technology Group(深圳證券交易所代碼:300253)及其投資回報率趨勢時,我們並不十分興奮。
Understanding Return On Capital Employed (ROCE)
了解資本使用回報率 (ROCE)
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. To calculate this metric for Winning Health Technology Group, this is the formula:
爲了澄清一下你是否不確定,ROCE是評估公司從投資於其業務的資本中獲得多少稅前收入(按百分比計算)的指標。要計算 Winning Health Technology Group 的這一指標,公式如下:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)
0.023 = CN¥149m ÷ (CN¥7.9b - CN¥1.4b) (Based on the trailing twelve months to September 2023).
0.023 = 1.49億元人民幣 ÷(79億元人民幣-14億元人民幣) (基於截至2023年9月的過去十二個月)。
So, Winning Health Technology Group has an ROCE of 2.3%. In absolute terms, that's a low return and it also under-performs the Healthcare Services industry average of 11%.
因此,威寧健康科技集團的投資回報率爲2.3%。從絕對值來看,這是一個低迴報,其表現也低於醫療服務行業11%的平均水平。
In the above chart we have measured Winning Health Technology Group's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Winning Health Technology Group .
在上圖中,我們將Winning Health Technology Group之前的投資回報率與之前的表現進行了對比,但可以說,未來更爲重要。如果你想了解分析師對未來的預測,你應該查看我們爲Winning Health Technology Group提供的免費分析師報告。
What The Trend Of ROCE Can Tell Us
ROCE 的趨勢能告訴我們什麼
When we looked at the ROCE trend at Winning Health Technology Group, we didn't gain much confidence. To be more specific, ROCE has fallen from 11% over the last five years. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It may take some time before the company starts to see any change in earnings from these investments.
當我們查看Winning Health Technology Group的投資回報率趨勢時,我們並沒有獲得太大的信心。更具體地說,投資回報率已從過去五年的11%下降了。同時,該業務正在使用更多的資本,但在過去的12個月中,這並沒有對銷售產生太大影響,因此這可能反映出長期投資。公司可能需要一段時間才能開始看到這些投資的收益發生任何變化。
Our Take On Winning Health Technology Group's ROCE
我們對贏家健康科技集團投資回報率的看法
To conclude, we've found that Winning Health Technology Group is reinvesting in the business, but returns have been falling. Since the stock has declined 27% over the last five years, investors may not be too optimistic on this trend improving either. On the whole, we aren't too inspired by the underlying trends and we think there may be better chances of finding a multi-bagger elsewhere.
總而言之,我們發現Winning Health Technology Group正在對該業務進行再投資,但回報率一直在下降。由於該股在過去五年中下跌了27%,因此投資者對這一趨勢的改善可能也不太樂觀。總的來說,我們對潛在趨勢的啓發不大,我們認爲在其他地方找到多袋裝機的可能性更大。
On a final note, we've found 2 warning signs for Winning Health Technology Group that we think you should be aware of.
最後,我們發現了Winning Health Technology Group的兩個警告信號,我們認爲你應該注意這些信號。
While Winning Health Technology Group isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.
儘管Winning Health Technology Group的回報率並不高,但請查看這份免費清單,列出了資產負債表穩健的股本回報率高的公司。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。